News from the life sciences community north of Boston
August 2022
Not long after announcing $625 million in Series D financing, Resilience has announced a strategic collaboration with Mayo Clinic to deliver novel biotherapeutics for rare and complex conditions. Announced yesterday, the focus of the partnership will be on therapies derived from biologics - cells, blood, enzymes, tissues, genes, or genetically engineered cells - for use in medicines.

"By combining our organizations' capabilities in biomanufacturing and medical innovation, we have an opportunity to deliver complex and innovative therapies to patients in need," said Rahul Singhvi, Sc.D., chief executive officer of Resilience.

Resilience is headquartered in San Diego, CA with locations in Allston and Waltham, MA. Read more in Endpoints News.
3EO Health Emerges from Stealth Mode
Licenses technology from Harvard's Wyss Institute for Biologically Inspired Engineering to deliver portable molecular testing
Following the recent launch of 3EO Health (48 Dunham Ridge, Beverly), the company announced a licensing agreement that will enable the commercialization of a portable, ultrasensitive nucleic acid detection technology.

Starting with a device to detect COVID-19, 3EO Health will provide a platform that could empower patients and doctors to more quickly access self-testing, results, and information through at-home molecular testing with PCR-grade sensitivity and antigen test-level cost.

Read more about the licensing agreement with Harvard University's Office of Technology Development in an announcement from the Wyss Institute for Biologically Inspired Engineering.
The 3EO Health team (front row, l to r): John Wu, head of finance; Thomas Schaus, Ph.D., director of research and scientific co-founder; Pete Honkanen, CTO; Jeremy Schubert, M.B.A., M.P.H., CEO; Lanning Levine, head of human resources; and Dennis Shay, Ph.D., director of regulatory affairs.
Asymchem Group, a leading global CMC/CDMO providing fully integrated solutions in chemical-pharmaceutical and biologic sectors, is planning to occupy to a 16,000 SF lab and office suite at 10 Gill Street in Woburn. The company's solutions range from early clinical stage to commercial stage, including R&D and cGMP production of advanced intermediates, APIs, formulations, as well as clinical research services.

Peng Dai, Ph.D. is executive director for Asymchem Boston R&D Center.
Emugen Therapeutics (175 New Boston Street, Woburn) is a discovery research company developing revolutionary treatments for patients with genetic disorders. The team is leveraging novel genetic and chemogenetic technologies to develop safe and effective gene therapies. The company was previously located in Cambridge.

Tyler Brown, Ph.D. is Emugen's chief operating officer.
An article in Bloomberg highlights GreenLight Biosciences' use of COVID vaccine technology to target parasites partly blamed for the bee crisis. The company is developing an RNA-based syrup to attack varroa mites, which feed off honeybees while spreading diseases. The RNA disrupts the mites ability to lay offspring that attach to bees.
"Without bees, 30 percent of the world's food goes away and most of the quality foods we're supposed to eat goes away. These varroa mites are not going to go away on their own."

Senior Vice President of Technology and External Innovation, GreenLight Biosciences
In additional news, GreenLight, a public benefit corporation based at 200 Boston Avenue, Medford, announced on Friday new funding of approximately $109 million.
A recent article in Forbes featured the efforts of Riley Kirk, Ph.D. and Miyabe Shields, Ph.D. of Real Isolates (48 Dunham Ridge, Beverly) to make cannabis pharmacology accessible. The duo are using platforms like TikTok and Instagram to help followers understand cannabis pharmacology, while gathering unique data on their experiences with it.
Jim Ellard, long-time Chief Executive Officer of New England Biolabs (NEB), retires this month after 39 years with the company, including 17 as CEO. He will remain chairman of the board.

Jim will be succeeded by Salvatore (Sal) Russello. Ph. D. (below), who most recently served as NEB's director of OEM & customized solutions. Sal joined NEB in 2007 as associate director of business development. Prior to NEB, he was director of reagent marketing at Caliper Life Sciences, now part of PerkinElmer, and before that, business development manager at Cell Signaling Technology.

NEB is headquartered in Ipswich, MA with a research and development facility at 43/44 Dunham Ridge, Beverly.
"I'm humbled by the trust that Jim and the Board have placed in me to uphold the reputation that NEB has earned over the last half century. As CEO, I will ensure that we continue to be guided by a strong sense of purpose to enable research, advance science, value every employee, and grow sustainably."

Sal Russello
CEO, New England Biolabs
Join Cummings Properties and Essex County Brewing Company for two pop up beer garden events in Beverly.

Raise a glass and meet your neighbors on Thursday, August 18 at 100 Cummings Center (near People's United Bank and J. Barrett Realty) and Thursday, August 25 at 48 Dunham Ridge (at the front parking area in front of the building). Both events will run from 3:00 PM to 6:00 PM.
Life sciences connector Josh Lang hosts the latest virtual BioXchange networking event Wednesday, August 31, from 4:00 PM to 7:00 PM. This premier life sciences networking organization helps connect companies and individuals within the Massachusetts and globally. Register.
Save the date! Cummings is pleased to sponsor the upcoming MassBio Regional Mixer at Old Planters Brewing Company in Beverly. Connect with coworkers, network with other life sciences professionals in the area, or just kick back. Appetizers and drinks will be served. Thursday, September 22, from 5:00 PM to 7:00 PM. This event is free for MassBio members. Register.
Now in its sixth year, Boston Startup Week is coming September 19-23, 2022. The free program features panels, workshops, presentations, and networking events with something for everyone. Founders, startup employees, investors, mentors, and students are welcome. Programs will be both in-person and virtual. Register.
North Shore InnoVentures (100 Cummings Center, Beverly) welcomes new member FireCyte Therapeutics. FireCyte is an emerging biotechnology company developing novel treatment strategies focused on the role of microglia and neuroinflammation in progressive neurodegenerative diseases of the eye. The company is led by Bill Yelle, CEO (left) and Jonathan Levenson, Ph.D., CSO.
Congratulations to Christopher Runnells, board member and prior CEO of Suture Concepts (100 Cummings Center, Beverly), who was recently appointed president of Maruho Medical. Maruho Medical is the U.S. orthopedic subsidiary of Maruho Co., Ltd, a leading Japanese pharmaceutical company. The company is focused on designing, manufacturing, and marketing disruptive technologies that advance soft tissue repair procedures.
In a recent MassBio guest blog, Gordon Carlson, vice president of business development, and Julia Varady, director of communications for Rilas Technologies, shared insights on "Changing Dynamics in Incubators and Outsourcing."

Rilas is currently building out a new facility at 400 West Cummings Park, Woburn. The lab will include incubator space for biotech companies, integrating the traditional incubator model with the unique analytical and purification capabilities that Rilas has perfected over the decades.
Have news to share? Please let us know! We are interested in company news, personnel changes, product launches, funding updates, events, and more. Contact Sue Howland, client engagement manager, at to share your news for upcoming newsletters. We look forward to hearing from you.
Keep up with news from the Cummings community by following us on LinkedInFacebookTwitter, and Instagram.